The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II

Biochemical Pharmacology

Volumn 46, Issue 8, 1993, Pages 1403-1412

  Larsen, Annette Kragh ^a   Grondard, Lucile ^b   Couprie, Jeannine ^f   Desoize, Bernard ^c,d   Comoe, Leopold ^c,e   Jardillier, Jean Claude ^c,d   Riou, Jean François ^b  

^a CNRS   (France)

^b SANOFI   (France)

^c Laboratoire de Pharmacognosie   (France)

^d INSTITUT JEAN GODINOT   (France)

^e Faculte de Pharmacie   (France)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

9 HYDROXYELLIPTICINE; AMSACRINE; ANTILEUKEMIC AGENT; ANTINEOPLASTIC ALKALOID; CAMPTOTHECIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETHIDIUM BROMIDE; FAGARONINE;

ANIMAL CELL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CATALYSIS; CATTLE; CHINESE HAMSTER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DNA INTERACTION; DRUG MECHANISM; ENZYME INHIBITION; FIBROSARCOMA; INTERCALATION COMPLEX; LEUKEMIA P 388 CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYMUS;

ALKALOIDS; ANIMAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CATALYSIS; CATTLE; COMPARATIVE STUDY; CRICETULUS; DNA; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE; FIBROSARCOMA; HAMSTERS; INTERCALATING AGENTS; LEUKEMIA P388; MICE; SUPPORT, NON-U.S. GOV'T; TUMOR CELLS, CULTURED;

EID: 0027369170     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-2952(93)90105-6     Document Type: Article

References (49)

1. Fagaronine, a new tumor inhibitor isolated from Fagara xanthoxyloides Lam. (Rutaceae)
2. Interaction of the antileukemic alkaloid, 2-hydroxy-3,8,9-trimethoxy-5-methylbenzo [c] phenanthridine (fagaronine) with nucleic acids
3. Effect of fagaronine on chromosome breaks and loss in Drosophila melanogaster
4. New natural products under development at the National Cancer Institute
5. The antileukemic alkaloid fagaronine and the human K562 leukemic cells effects on growth and induction of erythroid differentiation
6. Effect of fagaronine on cell cycle progression of human erythroleukemia K562 cells
7. Fagaronine, a novel antileukaemic alkaloid
8. Effects of the antitumor drugs 3-nitrobenzothiazolo (32-a) quinolinium and fagaronine on nucleic acid and protein synthesis
9. Inhibition of mammalian and oncornavirus nucleic acid polymerase activities by alkoxybenzophenanthridine alkaloids
10. Inhibition of reverse transcriptase activity of RNA-tumor viruses by fagaronine
11. Comparative study of Kinetoplast DNA in culture, blood and intracellular forms of Trypanosoma cruzi
12. Inhibition of eukaryotic DNA topoisomerases I and II activities by indoloquinolinedione derivatives
13. Purification and characterization of a type II DNA topoisomerase from bovine calf thymus
14. Purification and characterization of Plasmodium berghei DNA topoisomerases I and II: drug action, inhibition of decatenation and relaxation, and stimulation of DNA cleavage
15. The change of the torsion of the DNA helix caused by intercalation
16. A fluorescent complex between ethidium bromide and nucleic acids
17. Effects of the DNA intercalators 4′-(9-acridinylamino)methane-sulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage
18. Isolation and properties of Chinese hamster lung cells resistant to ellipticine derivatives
19. Sequential modifications of topoisomera I activity in a camptothecin resistant cell line established by progressive adaptation
20. DNA topoisomerase II immunostaining in human leukemia and Rhabdomyosarcoma cell lines and their responses to topoisomerase II inhibitors
21. Inhibition of the reactions catalyzed by a type I topoisomerase and a catenating enzyme of Trypanosoma cruzi by DNA-intercalating drugs. Preferential inhibition of the catenating reaction
22. Reduced formation of protein-associated DNA strand breaks in Chinese hamster cells resistant to topoisomerase II inhibitors
23. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors
24. Reduced DNA topoisomerase II activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells
25. DNA-Drug recognition and effects on topoisomerase II-mediated cytotoxicity
26. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II
27. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions
28. DNA unwinding and inhibition of mouse leukemia L1210 topoisomerase I by intercalators
29. Effects of morphotinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II
30. Inhibition of mammalian DNA topoisomerases I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus
31. DNA intercalating anti-tumour agents
32. DNA topoisomerase II mutant of Saccharomyces cerevisiae: topoisomerase II is required for segregation of daughter molecules at the termination of DNA replication
33. DNA topoisomerase II is required at the time of mitosis in yeast
34. In vivo exposure to four ellipticine derivatives with topoisomerase inhibitory activity results in chromosome clumping and sister chromatid exchange in murine bone marrow cells
35. Novobicin- and phorbol-12-myristate-13-acetate induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity
36. Suramin causes inhibition of HL-60 transferrin receptor expression and cell growth and stimulates partial cellular differentiation
37. + monomyelocytic leukemia cells by inhibitors of topoisomerase II
38. Interaction of DNA intercalator 3-nitrobenzothiazolo (3,2-a) quinolinium with DNA topoisomerases: a possible mechanism for its biological activity
39. Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin
40. Induction of differentiation and DNA strand breakage in human HL-60 and K-562 leukemia cells by genistein
41. Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells
42. Differentiation of human promonocytic leukemia U-937 cells with DNA topoisomerase II inhibitors: induction of vimentin gene expression
43. The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells
44. Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells
45. Induction of erythropoietin receptors during aclacinomycin-mediated erythroid differentiation of K562 leukemia cells
46. Energy coupling in DNA gyrase and the mechanism of action of novobiocin
47. Suramin is an inhibitor of DNA topoisomerase II In uitro and in Chinese hamster fibrosarcoma cells
48. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulion-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
49. HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis